Latest stories on DBVT
DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap
Seeking Alpha63 · neutralanalyst
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside
Seeking Alpha66 · bullishanalyst
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales | DBVT Stock News
StockTitan28 · bearishgeneral
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
DBV Technologies S.A. (DBVTF) files 8-K
SEC 8-K50 · neutralgeneral
DBV Technologies GAAP EPS of -$0.12 beats by $0.06
Seeking Alpha56 · neutralearnings
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update | DBVT Stock News
StockTitan34 · bearishearnings
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF | DBVT Stock News
StockTitan50 · neutralgeneral
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
Seeking Alpha56 · neutralproduct/pr
DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies
Morningstar56 · neutralproduct/pr
DBV Advances VIASKIN Peanut Patch Toward FDA Submission
TipRanks67 · bullishproduct/pr
DBV Technologies S.A. (DBVTF) files 8-K
SEC 8-K50 · neutralgeneral
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index | DBVT Stock News
StockTitan56 · neutralgeneral
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | DBVT Stock News
StockTitan55 · neutralgeneral
DBV Technologies Announces the Results of its 2026 Combined General Meeting | DBVT Stock News
StockTitan50 · neutralgeneral